Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement.
Alice T. Shaw(Dana-Farber Cancer Institute), Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), Marileila Varella‐Garcia(University of Colorado Anschutz Medical Campus), Jeffrey A. Engelman(Cancer Research Center), Geoffrey I. Shapiro(Brigham and Women's Hospital), Benjamin Solomon(Peter MacCallum Cancer Centre), Kristin Bergethon(Massachusetts General Hospital), Yung‐Jue Bang(Seoul National University), L. Tye(Pfizer (United States)), A. John Iafrate(Massachusetts General Hospital), Keith D. Wilner(Pfizer (United States)), D. Ross Camidge(University of Colorado Denver), Jeffrey W. Clark(Massachusetts General Hospital), Patricia Stephenson(Rho (United States)), Weiwei Tan(Memorial Sloan Kettering Cancer Center), Eunice L. Kwak(Harvard University), Ravi Salgia(City Of Hope National Medical Center)
Cited by 129
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k